{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:06:59Z","timestamp":1784038019429,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270551"],"award-info":[{"award-number":["82270551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2024SF-GJHX-16"],"award-info":[{"award-number":["2024SF-GJHX-16"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project","award":["2025ZD01906300"],"award-info":[{"award-number":["2025ZD01906300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02154-8","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:05:49Z","timestamp":1780052749000},"page":"1714-1724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fenofibrate discontinuation and the association with clinical outcomes in primary biliary cholangitis patients receiving combination therapy"],"prefix":"10.1007","volume":"48","author":[{"given":"Shuhao","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanya","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"10457","key":"2154_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ma X, Takahashi A, et al. Primary biliary cholangitis. Lancet. 2024;404(10457):1053\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)01303-5.","journal-title":"Lancet"},{"issue":"10","key":"2154_CR2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","volume":"70","author":"PJ Trivedi","year":"2021","unstructured":"Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut. 2021;70(10):1989\u20132003. https:\/\/doi.org\/10.1136\/gutjnl-2020-322362.","journal-title":"Gut"},{"issue":"3","key":"2154_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long\u2010term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u20137. https:\/\/doi.org\/10.1002\/hep.22428.","journal-title":"Hepatology"},{"issue":"4","key":"2154_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281\u20137. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.003.","journal-title":"Gastroenterology"},{"issue":"23","key":"2154_CR5","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1714519.","journal-title":"N Engl J Med"},{"issue":"2","key":"2154_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/liv.12290","volume":"34","author":"S Lens","year":"2014","unstructured":"Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34(2):197\u2013203. https:\/\/doi.org\/10.1111\/liv.12290.","journal-title":"Liver Int"},{"issue":"9","key":"2154_CR7","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/apt.16618","volume":"54","author":"JA Sorda","year":"2021","unstructured":"Sorda JA, Gonz\u00e1lez Ballerga E, Barreyro FJ, et al. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. Aliment Pharmacol Ther. 2021;54(9):1202\u201312. https:\/\/doi.org\/10.1111\/apt.16618.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2154_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.13465","volume":"43","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43(2):283\u201393. https:\/\/doi.org\/10.1111\/apt.13465.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2154_CR9","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","volume":"61","author":"VS Hegade","year":"2016","unstructured":"Hegade VS, Khanna A, Walker LJ, et al. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci. 2016;61(10):3037\u201344. https:\/\/doi.org\/10.1007\/s10620-016-4250-y.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"2154_CR10","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/hep4.2103","volume":"6","author":"D Ding","year":"2022","unstructured":"Ding D, Guo G, Liu Y, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol Commun. 2022;6(12):3487\u201395. https:\/\/doi.org\/10.1002\/hep4.2103.","journal-title":"Hepatol Commun"},{"issue":"11","key":"2154_CR11","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Guo G, Zheng L, et al. Effectiveness of Fenofibrate in treatment-naive patients with Primary Biliary Cholangitis: a randomized clinical trial. Am J Gastroenterol. 2023;118(11):1973\u20139. https:\/\/doi.org\/10.14309\/ajg.0000000000002238.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2154_CR12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.cgh.2022.07.038","volume":"21","author":"N Abbas","year":"2023","unstructured":"Abbas N, Culver EL, Thorburn D, et al. UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023;21(6):1561-1570.e13. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.038.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2154_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423\u201331. https:\/\/doi.org\/10.1038\/ajg.2015.20.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2154_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/liv.14871","volume":"41","author":"AF Carrion","year":"2021","unstructured":"Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int. 2021;41(6):1335\u201343. https:\/\/doi.org\/10.1111\/liv.14871.","journal-title":"Liver Int"},{"issue":"10","key":"2154_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101168","volume":"6","author":"SB Roberts","year":"2024","unstructured":"Roberts SB, Choi WJ, Worobetz L, et al. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis. JHEP Rep. 2024;6(10):101168. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101168.","journal-title":"JHEP Rep"},{"issue":"7","key":"2154_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00535-023-01999-4","volume":"58","author":"KA Kim","year":"2023","unstructured":"Kim KA, Choi HY, Ki M, et al. Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019. J Gastroenterol. 2023;58(7):682\u201392. https:\/\/doi.org\/10.1007\/s00535-023-01999-4.","journal-title":"J Gastroenterol"},{"issue":"4","key":"2154_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/apt.70391","volume":"63","author":"KV Kowdley","year":"2026","unstructured":"Kowdley KV, Ieyoub J, Pan Y, et al. Treatment persistence, normal alkaline phosphatase and clinical outcomes in primary biliary cholangitis. Aliment Pharmacol Ther. 2026;63(4):522\u201337. https:\/\/doi.org\/10.1111\/apt.70391.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2154_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419. https:\/\/doi.org\/10.1002\/hep.30145.","journal-title":"Hepatology"},{"issue":"9","key":"2154_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.gastrohep.2023.01.001","volume":"46","author":"D Ding","year":"2023","unstructured":"Ding D, Ren P, Guo G, et al. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid. Gastroenterol Hepatol. 2023;46(9):692\u2013701. https:\/\/doi.org\/10.1016\/j.gastrohep.2023.01.001.","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"2154_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","volume":"4","author":"F Rodriguez","year":"2019","unstructured":"Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206\u201313. https:\/\/doi.org\/10.1001\/jamacardio.2018.4936.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"2154_CR21","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/diacare.27.9.2149","volume":"27","author":"DT Lau","year":"2004","unstructured":"Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149\u201353. https:\/\/doi.org\/10.2337\/diacare.27.9.2149.","journal-title":"Diabetes Care"},{"issue":"1","key":"2154_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01219-w","volume":"20","author":"NL Allard","year":"2020","unstructured":"Allard NL, MacLachlan JH, Dev A, et al. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes. BMC Gastroenterol. 2020;20(1):140. https:\/\/doi.org\/10.1186\/s12876-020-01219-w.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"2154_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1509840.","journal-title":"N Engl J Med"},{"issue":"6","key":"2154_CR24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2011.02.031.","journal-title":"J Hepatol"},{"issue":"10","key":"2154_CR25","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186\u201394. https:\/\/doi.org\/10.1038\/ajg.2010.216.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2154_CR26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/hq1101.098228","volume":"21","author":"SM Post","year":"2001","unstructured":"Post SM, Duez H, Gervois PP, et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21(11):1840\u20135. https:\/\/doi.org\/10.1161\/hq1101.098228.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2154_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.26894","volume":"59","author":"NS Ghonem","year":"2014","unstructured":"Ghonem NS, Ananthanarayanan M, Soroka CJ, et al. Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59(3):1030\u201342. https:\/\/doi.org\/10.1002\/hep.26894.","journal-title":"Hepatology"},{"key":"2154_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/864839","volume":"2014","author":"K Chen","year":"2014","unstructured":"Chen K, Li J, Wang J, et al. 15-Deoxy-\u03b312,14-prostaglandin J2 Reduces Liver Impairment in a Model of ConA-Induced Acute Hepatic Inflammation by Activation of PPAR\u03b3 and Reduction in NF-\u03baB Activity. PPAR Res. 2014;2014:864839. https:\/\/doi.org\/10.1155\/2014\/864839.","journal-title":"PPAR Res"},{"issue":"2","key":"2154_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","volume":"33","author":"C Levy","year":"2011","unstructured":"Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33(2):235\u201342. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04512.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2154_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2019.04.001.","journal-title":"J Hepatol"},{"issue":"3","key":"2154_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u20137. https:\/\/doi.org\/10.1002\/hep.22428.","journal-title":"Hepatology"},{"issue":"4","key":"2154_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000826","volume":"80","author":"J Ampuero","year":"2024","unstructured":"Ampuero J, Lucena A, Berenguer M, et al. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy. Hepatology. 2024;80(4):791\u2013806. https:\/\/doi.org\/10.1097\/HEP.0000000000000826.","journal-title":"Hepatology"},{"issue":"11","key":"2154_CR33","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/apt.70120","volume":"61","author":"KV Kowdley","year":"2025","unstructured":"Kowdley KV, Victor DW 3rd, MacEwan JP, et al. Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: a population-based study. Aliment Pharmacol Ther. 2025;61(11):1775\u201384. https:\/\/doi.org\/10.1111\/apt.70120.","journal-title":"Aliment Pharmacol Ther"},{"key":"2154_CR34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390:795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185.","journal-title":"N Engl J Med"},{"key":"2154_CR35","doi-asserted-by":"publisher","first-page":"783794","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390:783794. https:\/\/doi.org\/10.1056\/NEJMoa2312100.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02154-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:00Z","timestamp":1784035860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02154-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2154"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02154-8","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study design was approved by the ethics committee of the Xijing Hospital of the Air Force Military Medical University (KY20151230-5).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}